In part 4 of our interview, we learn more about nipocalimab’s safety profile and how this investigative agent might address ...

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a recent ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...